title: Adding STING to the Tale of Oncolytic Virotherapy.
abstract: The identification of STING as a key cytoplasmic innate recognition molecule for DNA viruses whose function is lost in a variety of cancers has coincided with the approval of IMLYGIC for metastatic melanoma. This represents the first replication competent viral therapy approved for the treatment of any cancer in the US. The role of STING pathway in the selectivity of HSV has been addressed for the first time in Xia et al (1).
authors.affiliation: University of Pittsburgh, Departments of Cell Biology and Immunology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
authors.forename: Steve H
authors.initials: SH
authors.lastname: Thorne
keywords: HSV; Oncolytic Virus; STING; Vaccinia